About delcath systems - DCTH
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.
DCTH At a Glance
Delcath Systems, Inc.
566 Queensbury Avenue
Queensbury, New York 12804
| Phone | 1-212-489-2100 | Revenue | 85.23M | |
| Industry | Medical Specialties | Net Income | 2.70M | |
| Sector | Health Technology | 2025 Sales Growth | 129.085% | |
| Fiscal Year-end | 12 / 2026 | Employees | 156 | |
| View SEC Filings |
DCTH Valuation
| P/E Current | 142.456 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 149.408 |
| Price to Sales Ratio | 4.731 |
| Price to Book Ratio | 3.15 |
| Price to Cash Flow Ratio | 17.91 |
| Enterprise Value to EBITDA | 310.295 |
| Enterprise Value to Sales | 3.673 |
| Total Debt to Enterprise Value | 0.003 |
DCTH Efficiency
| Revenue/Employee | 546,352.564 |
| Income Per Employee | 17,307.692 |
| Receivables Turnover | 6.962 |
| Total Asset Turnover | 0.715 |
DCTH Liquidity
| Current Ratio | 10.916 |
| Quick Ratio | 9.98 |
| Cash Ratio | 8.314 |
DCTH Profitability
| Gross Margin | 86.159 |
| Operating Margin | 0.774 |
| Pretax Margin | 4.118 |
| Net Margin | 3.168 |
| Return on Assets | 2.263 |
| Return on Equity | 3.001 |
| Return on Total Capital | 2.407 |
| Return on Invested Capital | 2.971 |
DCTH Capital Structure
| Total Debt to Total Equity | 0.842 |
| Total Debt to Total Capital | 0.835 |
| Total Debt to Total Assets | 0.578 |
| Long-Term Debt to Equity | 0.751 |
| Long-Term Debt to Total Capital | 0.745 |